Navigation Links
The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients

t data and treatment protocols every two years.

VELCADE has been available to patients, who have relapsed after a previous treatment, in the United States since 2003 and in Europe since 2004. VELCADE as a single agent shows a median overall survival in this patient population of two and a half years (29.8 months) with "robust response rates" regardless of age. VELCADE in combination with DOXIL(R) was approved in May 2007. Data from a follow-up to a Phase 3 multi-national clinical trial shows that this combination further improves the probability of survival by 41%. Among the findings presented from an open label Phase I/II study evaluating 54 patients, when VELCADE is combined with melphalan and prednisone in newly diagnosed patients who do not go on to have transplants, survival was 85% the strongest 3 year survival rate demonstrated to date.

REVLIMID, an oral drug, is the newest of the novel therapies. This is the first conference since its European approval earlier this month; it is already approved in the United States for use in combination with dexamethasone as a treatment for multiple myeloma in patients who have been previously treated. Among the findings presented, in patients who have relapsed or not responded to a previous treatment, the 35 month median survival using REVLIMID in combination with dexamethasone has been characterized as the "highest response rate and longest overall survival" reported so far from two large randomized controlled Phase III trials that enrolled more than 700 patients worldwide. Importantly, it was previously reported that in patients newly diagnosed with multiple myeloma, in a large randomized Phase III trial evaluating more than 400 patients, REVLIMID with low dose dexamethasone demonstrated what has been called an "unprecedented" 98% one year survival in patients under 65 and 95% one year survival in patients 65 and over.

Combining these two powerful agents, VELCADE AND REVLIMID, produces "robust and du
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

Post Your Comments:
(Date:11/20/2009)..., , MINNEAPOLIS, Nov. 20 /PRNewswire-FirstCa...unced results for its first quarter ended Septembe... per diluted share, on revenues of $3,263,000. Th...per diluted share, on revenues of $3,168,000 for t... the first quarter results, Biotel President and C...
(Date:11/20/2009)..., , PRINCETON, N.J., Nov. 20 /PRNewswire-... SNGX) (Soligenix or the Company), formerly known ... company, announced today that it has formed a con...nce RiVax(TM) and other rapidly acting vaccines. S...tional Institute of Allergy and Infectious Disease...
(Date:11/19/2009)..., , TAINAN, Taiwan, Nov. 19 /PRNewswi...of active pharmaceutical ingredients (APIs), annou...ent Compound Safety Certification from,SafeBridge(...inoPharm,s,competency and proficiency in the safe ...ts (APIs), and applies to specific laboratories an...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2InsiteResearch Market Momentum Continues to Accelerate 14033 1InsiteResearch Market Momentum Continues to Accelerate 14033 2InsiteResearch Market Momentum Continues to Accelerate 14033 3Implantable Defibrillators May Not Help Women With Heart Failure 57116 1Implantable Defibrillators May Not Help Women With Heart Failure 57116 2Implantable Defibrillators May Not Help Women With Heart Failure 57116 3Forest ecologist sees climate consequences 9921 1
(Date:11/21/2009)...resident and chief executive officer of the Alzhei...wing statement regarding the inclusion of cognitiv...ellness for Medicare beneficiaries in "The Pa...t was introduced last night: , ...ic J. Hall, president and chief executive officer ...
(Date:11/21/2009)...sk whether there is a secret to ,alcohol rehab suc... London, UK (PRWEB) November 21, 2009 -- Lin...the adult UK population drinking enough alcohol to... disease*, it is hardly a surprise that many are i...nd residential centres for help. However, for some...
(Date:11/20/2009)...swire-FirstCall/ - NUCRYST Pharmaceuticals Corp. a...ers will be held on Monday, December 21, 2009. The... two special resolutions. The first special resolu...r substantially all of the assets of NUCRYST, subs...urchase agreement dated November 10, 2009 among th...
(Date:11/20/2009)...wswire-USNewswire/ -- The United States Conference...ntial changes its health reform bill in order to k...onscience protection on abortion, protect access t...ovisions for adequate affordability. ,, The bis...us disappointment" that creates new and unacceptab...
(Date:11/20/2009)...ngressmen in Competitive Re-election Battles Could... Washington, DC (Vocus) Novembe... re-election next year in races deemed to be compe... regret voting for House Speaker Nancy Pelosi&rsqu...y International/ O’Leary Report poll. (The...
Breaking Medicine News(10 mins):Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3
... at the root of higher stroke risk, study says , ...peated surges and drops in blood pressure and bloo...pnea more prone to have a stroke and die in their ... during episodes. When this happens, the organ,s b...
... and survive antibiotic attack when a protein flip...t state until treatment abates, researchers at The...report in the Jan.16 edition of Science . , "For...ichard Brennan, Ph.D., professor in M. D. Anderson...
...and operators of two Miami medical clinics, along ...eaded guilty to defrauding the Medicare program in...usion fraud scheme, Acting Assistant Attorney Gene... "Tony" Marrero, 41, Belkis Marrero, 41, and Luz B...
...m announces the availability of Trade Alerts on st...ll of the daily trading notes for free by visiting...ade Alerts include: Eli Lily & Co. (NYSE: LL...T ) and Dow Chemical Co. (NYSE: DOW ). , , Join...
...thers dying each year , , THURSDAY, Jan. 1...ne of the world,s poorest countries is 300 times m...han women living in more affluent nations, a UNICE...-fold higher chance of dying during their first mo...
...ial will examine solutions to the budgeting, forec...ted by adaptive studies. These challenges include ...nting for shifting resource allocations, timelines...inical trial software for clinical trial operation...
Other Medicine News:Health News:Sleep Apnea Seems to Wear Down the Brain 2Health News:E. coli persists against antibiotics through HipA-induced dormancy 2Health News:E. coli persists against antibiotics through HipA-induced dormancy 3Health News:Medical Clinic Executives and Worker Plead Guilty to $5.3 Medicare Fraud Scheme 2Health News:Medical Clinic Executives and Worker Plead Guilty to $5.3 Medicare Fraud Scheme 3Health News:Beacon Equity Issues Technical Trade Alerts on Headline Stocks: LLY, PCS, CAG, FRX, TGT, DOW 2Health News:Mothers, Newborns at High Risk in Developing World 2Health News:ClearTrial to Provide Guidelines for Accurately Forecasting and Budgeting Adaptive Clinical Trials at CBI Conference 2
SMZ-1500
...1.2W Corr was designed to have the following prope...ecimens (vital sections, cell cultures, specimens ...for compensating differences in cover glass thickn...24C and 37C). The correction collar can also be u...
Achroplan objectives
Fluar objectives
Medicine Products: